Novel conditioning regimens for Hodgkin’s and non-Hodgkin’s lymphoma

References

• 1  Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med.316,1493–1498 (1987).
  Medline CASGoogle Scholar
• 2  Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy. in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N. Engl. J. Med.333,1540–1545 (1995).
  Medline CASGoogle Scholar
• 3  Blay J, Gomez F, Sebban C et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood92,3562–3568 (1998).
  Medline CASGoogle Scholar
• 4  Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy andautologous stem-cell support. N. Engl. J. Med.350,1287–1295 (2004).
  Medline CASGoogle Scholar
• 5  Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOPB in aggressive B-cell lymphoma. N. Engl. J. Med.336(18),1290–1297 (1997).
  Medline CASGoogle Scholar
• 6  Oliansky DM, Czuczman M, Fisher RI et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol. Blood Marrow Transplant.17(1),20–47 (2011).
  MedlineGoogle Scholar
• 7  Sirohi B, Cunningham D, Powles R et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann. Oncol.19,1312–1319 (2008).
  Medline CASGoogle Scholar
• 8  Bartlett NL. Modern treatment of Hodgkin lymphoma. Curr. Opin. Hematol.15,408–414 (2008).
  MedlineGoogle Scholar
• 9  Moskowitz AJ, Yahalom J, Kewalramani T et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood116,4934–4937 (2010).
  Medline CASGoogle Scholar
• 10  Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet359,2065–2071 (2002).
  Medline CASGoogle Scholar
• 11  Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J. Natl Compr. Canc. Netw.9,1060–1071 (2011).
  Medline CASGoogle Scholar
• 12  A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. N. Engl. J. Med.329(14),987–994 (1993).
  MedlineGoogle Scholar
• 13  Blay J, Gomez F, Sebban C et al. The international. prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood92,3562–3568 (1998).
  Medline CASGoogle Scholar
• 14  Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J. Clin. Oncol.13(3),588–595 (1995).
  Medline CASGoogle Scholar
• 15  Chopra R, McMillan AK, Linch DC. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood81(5),1137–1145 (1993).
  Medline CASGoogle Scholar
• 16  Caballero MD, Rubio V, Rifon J. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant.20(6),451–458 (1997).
  Medline CASGoogle Scholar
• 17  Jo JC, Kang BW, Jang G. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann. Hematol.87,43–48 (2008).
  Medline CASGoogle Scholar
• 18  Carver JR, Shapiro CL, Ng A et al. American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Clin. Oncol.25,3991–4008 (2007).
  CASGoogle Scholar
• 19  Montoto S, Canals C, Rohatiner AZS et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study Leukemia21,2324–2331 (2007).
  Medline CASGoogle Scholar
• 20  Blijlevens N, Schwenkglenks M, Bacon P et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European blood and marrow transplantation mucositis advisory group. J. Clin. Oncol.26,1519–1525 (2008).
  Medline CASGoogle Scholar
• 21  Krishnan GS, Chaudhary V, Al-Janadi A et al. BCNU toxicity presenting with a large pericadial and pleural effusion. Ann. Transplant.13(1),44–47 (2008).
  MedlineGoogle Scholar
• 22  Till BG, Madtes DK. BCNU-associated pneumonitis: portrait of a toxicity. Leuk. Lymphoma53(6),1019–1020 (2012).
  MedlineGoogle Scholar
• 23  Parish JM, Muhm JR, Leslie KO. Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation. Mayo Clin. Proc.78,630–634 (2003).
  MedlineGoogle Scholar
• 24  Alessandrino EP, Bernasconi P, Colombo A et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant.25,309–313 (2000).
  Medline CASGoogle Scholar
• 25  Kehrer JP. The effect of BCNU (carmustine) on tissue glutathione reductase activity. Toxicol. Lett.17,63–68 (1983).
  Medline CASGoogle Scholar
• 26  Lekakis L, de Padua Silva L, de Lima M. Preparative regimens in hematopoietic stem cell transplantation. Curr. Pharm. Des.14,1923–1935 (2008).
  Medline CASGoogle Scholar
• 27  Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the Rituximab era. J. Clin. Oncol.28(27),4184–4190 (2010).
  MedlineGoogle Scholar
• 28  Press OW, Eary JF, Gooley T et al. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood96(9),2934–2942 (2000).
  Medline CASGoogle Scholar
• 29  Gopal AK, Rajendran JG, Petersdorf SH et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood99,3158–3162 (2002).
  Medline CASGoogle Scholar
• 30  Nadamanee A, Forman S, Molina A et al. A Phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood106(8),2896–2902 (2005).
  MedlineGoogle Scholar
• 31  Vose JM, Bierman PJ, Enke C et al. Phase I trial of Iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J. Clin. Oncol.23(3),461–467 (2005).
  Medline CASGoogle Scholar
• 32  Shimoni A, Zwas ST, Oksman Y et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for aggresisve chemo-refratory non Hodgkin’s lymphoma. Exp. Hematol.35(4),534–540 (2007).
  Medline CASGoogle Scholar
• 33  Krishnan A, Nademanee A, Fung HC et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. J. Clin. Oncol.26(1),90–95 (2008).
  Medline CASGoogle Scholar
• 34  Decaudin D, Mounier N, Tilly H et al. 90Y Ibritumomab Tiuxetan (Zevalin) combined With BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA Phase II prospective study. Clin. Lymphoma Myeloma Leuk.11(2),212–218 (2011).
  Medline CASGoogle Scholar
• 35  Shimoni A, Avivi I, Rowe JM et al. A randomizedstudy comparing yttrium-90 ibritumomab tiuxetan (Zevali) and high dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lympoma. Cancer118(19),4706–4714 (2012).
  Medline CASGoogle Scholar
• 36  Khouri IFS, Salina RM, Hsing C et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-Cell non Hodgkin lympoma. J. Clin. Oncol.23(10),2240–2247 (2005).
  Medline CASGoogle Scholar
• 37  Vose JM, Carter S, Burns LJ et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J. Clin. Oncol.31(13),1662–1668 (2013).
  Medline CASGoogle Scholar
• 38  Krishnan A, Palmer JM, Ni-Chun Tsai et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation–based conditioning for poor-risk diffuse large cell lymphoma. Biol. Blood Marrow Transplant.18,441–450 (2012).
  MedlineGoogle Scholar
• 39  Ramzi M, Mohamadian M, Vojdani R et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp. Clin. Transplant.2,163–167 (2012).
  Google Scholar
• 40  Di Ianni M, Ballanti S, Iodice G et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin’s lymphoma. Hematology17(1),23–27 (2012).
  Medline CASGoogle Scholar
• 41  Kremens B, Wieland R, Reinhard H et al. High-dose chemotherapy with autologousstem cell rescue in children with retinoblastoma. Bone Marrow Transplant.31,281–284 (2003).
  Medline CASGoogle Scholar
• 42  Fontelonga A, Kelly AJ, MacKintosh FR et al. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin’s lymphoma. Bone Marrow Transplant.19,983–988 (1997).
  Medline CASGoogle Scholar
• 43  Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am. J. Clin. Oncol.28,130–137 (2005).
  Medline CASGoogle Scholar
• 44  Falzetti F, Di Ianni M, Ballanti S et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin. Exp. Med.12(3),165–171 (2012).
  Medline CASGoogle Scholar
• 45  Soussain C, Hoang-Xuan K, Taillandier L et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: societe française de greffe de moelle osseuse-thèrapie cellulaire. J. Clin. Oncol.26(15),2512–2518 (2008).
  MedlineGoogle Scholar
• 46  Korfel A, Elter T, Thiel E et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell tranplantation for CNS relapse of aggressive lymphomas. Haematologica98(3),364–370 (2013).
  Medline CASGoogle Scholar
• 47  Reddy N, Savani BN. Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT. Bone Marrow Transplant.47(10),1265–1268 (2012).
  Medline CASGoogle Scholar
• 48  Tombleson RL, Green MR, Fancher KM. Putting caution in TEAM: high-dose chemotherapy with autologous HSCT for primary central nervous system lymphoma. Bone Marrow Transplant.48,1–2 (2012).
  Google Scholar
• 49  Ferreri AJM, Crocchiolo R, Assanelli A, Govi S, Reni M. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk. Lymphoma49,2042–2047 (2008).
  Medline CASGoogle Scholar
• 50  Carella AM, Palumbo G, Merla E et al. TEAM (thiotepa, etoposide, cytarabine, melphalan) as conditioning regimen for lymphoma treatment with autologous haematopoietic stem cell transplantation. Haematologica94(Suppl. 2),66 (2009) (Abstract 0172).
  Google Scholar
• 51  Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res.14(1),309–317 (2008).
  Medline CASGoogle Scholar
• 52  Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocitic leukemia (CLL): a multicenter Phase II trial of the German CLL study group [abstract]. Blood112, (2008) (Abstract 130).
  Google Scholar
• 53  Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantlecell and low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol.23(15),3383–3389 (2005).
  Medline CASGoogle Scholar
• 54  Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J. Clin. Oncol.26(27),4473–4479 (2008).
  Medline CASGoogle Scholar
• 55  Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a Phase II multicenter, single-agent study. J. Clin. Oncol.26(2),204–210 (2008).
  Medline CASGoogle Scholar
• 56  Visani G, Malerba L, Stefani PM et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood118(12),3419–3425 (2011).
  Medline CASGoogle Scholar
• 57  Hayes MT, Bartley J, Parsons PG, Eaglesham GK, Prakash AS. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry36,10646–10654 (1997).
  Medline CASGoogle Scholar
• 58  Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem.23,682–684 (1980).
  Medline CASGoogle Scholar
• 59  Meulemans A, Giroux B, Hannoun P, Robine D, Henzel D. Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human, and rat brain biopsies. Chemotherapy37,86–92 (1991).
  Medline CASGoogle Scholar
• 60  Meulemans A, Giroux B, Hannoun P, Henzel D, Bizzari JP, Mohler J. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Chemotherapy35,313–319 (1989).
  Medline CASGoogle Scholar
• 61  Guaitani A, Corada M, Lucas C, Lemoine A, Garattini S, Bartosek I. Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma. Cancer Chemother. Pharmacol.28,293–297 (1991).
  Medline CASGoogle Scholar
• 62  Boutin JA, Norbeck K, Moldeus P et al. Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. Eur. J. Cancer Clin. Oncol.25,1311–1316 (1989).
  Medline CASGoogle Scholar
• 63  Brandes AA, Tosoni A, Franceschi E et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a Phase II trial of gruppo Italiano cooperativo di neuro-oncologia (GICNO). Cancer Chemother. Pharmacol.64,769–775 (2009).
  Medline CASGoogle Scholar
• 64  Fabrini MG, Silvano G, Lolli I et al. A multi-institutional Phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J. Neurooncol.92,79–86 (2009).
  Medline CASGoogle Scholar
• 65  Scoccianti S, Detti B, Sardaro A et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs19,613–620 (2008).
  Medline CASGoogle Scholar
• 66  Jacquillat C, Khayat D, Weil M, Bizzari JP. Clinical Phase I–II study of the nitrosourea servier 10036 (fotemustine) in hematological malignancies. Proc. ECCO4,314 (1987).
  Google Scholar
• 67  Rigal-Huguet F, Gaspard MH, Attal M, Giroux B, Lucas C, Pris J. Clinical pharmacokinetics of high doses of fotemustine with assessment of passage across the blood-brain barrier. Bull. Cancer77,599 (1990).
  Google Scholar
• 68  Musso M, Scalone R, Marcacci G et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patient undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant.45,1147–1153 (2010).
  Medline CASGoogle Scholar